SHANGHAI JUNSHI BIO YC1 - Asset Resilience Ratio
SHANGHAI JUNSHI BIO YC1 (8SJ) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SHANGHAI JUNSHI BIO YC1 (8SJ) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how SHANGHAI JUNSHI BIO YC1's Asset Resilience Ratio has changed over time. See 8SJ equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down SHANGHAI JUNSHI BIO YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 8SJ market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €600.78 Million | 4.85% |
| Total Liquid Assets | €600.78 Million | 4.85% |
Asset Resilience Insights
- Limited Liquidity: SHANGHAI JUNSHI BIO YC1 maintains only 4.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SHANGHAI JUNSHI BIO YC1 Industry Peers by Asset Resilience Ratio
Compare SHANGHAI JUNSHI BIO YC1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for SHANGHAI JUNSHI BIO YC1 (2024–2025)
The table below shows the annual Asset Resilience Ratio data for SHANGHAI JUNSHI BIO YC1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.85% | €600.78 Million ≈ $702.38 Million |
€12.40 Billion ≈ $14.50 Billion |
+0.86pp |
| 2024-12-31 | 3.99% | €430.51 Million ≈ $503.31 Million |
€10.80 Billion ≈ $12.63 Billion |
-- |
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more